Opsoclonus-Myoclonus Syndrome

This is a rare neurological condition affecting movement and eye movements. It causes very fast, jerky, and uncontrolled eye movements, often described as 'dancing eyes'. It also causes muscle jerks and makes walking unsteady. It can be linked to infections or tumors in the brain.

Condition

What people with Opsoclonus-Myoclonus Syndrome report

Every report comes from a Lived member, sent anonymously.

Have you tried IVIG for Opsoclonus-Myoclonus Syndrome?

NameHow it went

About Opsoclonus-Myoclonus Syndrome

What It Is

Opsoclonus-myoclonus syndrome (OMS) is a rare disorder in which the immune system mistakenly attacks parts of the nervous system that coordinate movement. Its name describes its two hallmark signs: opsoclonus, rapid and chaotic darting of the eyes in every direction, and myoclonus, brief shock-like jerks of the muscles. Most people also develop ataxia, an unsteadiness that can make walking, standing or even sitting difficult. The combination gave it the older name dancing eyes-dancing feet syndrome, and it is also called opsoclonus-myoclonus-ataxia syndrome or Kinsbourne syndrome. OMS most often affects young children, usually around 18 months to 2 years old. Symptoms often come on quickly, over days to weeks. A toddler who was walking may start staggering, fall often or refuse to stand, and many become extremely irritable, cry inconsolably and sleep poorly. Speech may slur or be lost for a time. Adults can develop OMS too, often with dizziness, nausea, vision problems and a trembling, unsteady walk. Because it can affect development in children and can signal a hidden tumor at any age, prompt diagnosis matters.

Causes & Risk Factors

OMS is an autoimmune reaction rather than an inherited or degenerative disease. In about half of children, the trigger is a small tumor of developing nerve tissue called neuroblastoma, or a related tumor such as ganglioneuroblastoma. These tumors sit outside the brain, usually in the chest, abdomen or adrenal glands. The immune response against the tumor seems to cross-react with the brain, which may also be why these tumors are usually small, low-stage and very treatable. In other children no tumor is found, and the illness may follow a viral or bacterial infection. A recent infection does not rule out a tumor, though, since both can be present. In adults, OMS is most often linked to cancer elsewhere in the body, most commonly lung or breast cancer, and these cancers are often more serious than the tumors seen in children. It can also follow infections, including HIV, or occur with no identifiable cause.

How It's Diagnosed

There is no single test for OMS. The diagnosis rests on recognizing the pattern: the chaotic eye movements, muscle jerks or unsteadiness, behavior or sleep changes, and, in children, a neuroblastic tumor. Early on, OMS is often mistaken for acute cerebellar ataxia, a common and usually self-limited unsteadiness after a viral illness in children. The appearance of opsoclonus separates the two. Because the eye movements can come and go, a smartphone video recorded at home can help the clinician see them. A neurologist usually orders a brain MRI, which is typically normal in OMS but rules out other causes, and a lumbar puncture (spinal tap) to look for signs of inflammation and exclude infection. The most important step for a child is a careful search for a tumor, ideally with high-resolution MRI or CT from the neck to the pelvis. Urine tests for substances that neuroblastomas release are often negative with the small tumors linked to OMS, so a normal urine test does not rule one out. If no tumor is found at first, imaging may be repeated a few months later. Adults are evaluated for cancer, often with CT or PET scanning, and blood tests for antibodies linked to cancer-related neurological syndromes.

Treatment Options

Treatment aims to calm the immune attack quickly and keep it calm. Experts recommend starting immunotherapy as soon as possible, because ongoing symptoms reflect active inflammation and delays may worsen long-term outcomes. There is no single proven regimen, and approaches differ. Many North American centers start several treatments at once, while others begin with one and add more if the response is not enough. Common building blocks include high-dose corticosteroids (such as dexamethasone or methylprednisolone) or ACTH (corticotropin, a hormone injection that prompts the body to make its own steroids); intravenous immunoglobulin (IVIG), donated antibodies given by infusion; and rituximab, an infused antibody that depletes the B cells thought to drive the disease. In one trial of children with tumor-associated OMS, adding IVIG to standard treatment roughly doubled the response rate. Cyclophosphamide, a stronger immune-suppressing drug, is used less often now because of concerns including effects on fertility. These treatments carry trade-offs: long courses of steroids or ACTH can cause weight gain, high blood pressure and bone thinning, and rituximab can lower antibody levels and raise infection risk, so blood counts and immune levels are monitored. If a tumor is found in a child, it is usually removed surgically, and chemotherapy is rarely needed. Removing the tumor alone usually does not settle the neurological symptoms, so immunotherapy is still required. Adults with an underlying cancer need cancer treatment alongside immunotherapy, and medicines such as clonazepam, a sedative, may ease jerks while immune treatment takes effect. Physical, occupational and speech therapy support recovery of movement and communication.

What to Expect

Most children improve with treatment, and children whose OMS was linked to neuroblastoma almost always survive the tumor. Recovery of the nervous system is slower and less predictable. Treatment typically continues for at least a year, then is reduced gradually, because tapering too fast is a common trigger for symptoms to return. Relapses happen in a large share of children, often during or just after a common viral illness. A brief flare during a fever that clears as the fever goes away is not usually counted as a relapse. Relapses can occur years later, so long-term follow-up continues. Movement usually recovers fairly well, though some clumsiness, tremor or fine-motor difficulty may remain. The larger long-term challenge for many children is learning, language, attention and behavior, which can be affected even when movement has largely recovered. More relapses are linked to poorer outcomes, which is one reason treatment aims for complete, lasting remission. Ongoing therapies, neurocognitive testing before school age and early school support plans help children make the most of their abilities. Routine vaccinations are usually paused during treatment and planned with the care team afterward. For adults, many reach remission with immunotherapy, but the outlook also depends heavily on whether an associated cancer is present and how it responds to treatment.

When to Seek Help

Arrange same-day medical evaluation if a child or adult develops rapid, darting, jumbled eye movements, a sudden inability to walk steadily, or new muscle jerks or shaking, especially together with marked irritability or sleep changes in a young child. If a child diagnosed with acute cerebellar ataxia develops these eye movements or jerks, or is not improving after a couple of weeks, return for reassessment. For someone already diagnosed, contact the care team promptly if eye movements, jerks, unsteadiness, irritability or sleep problems return or worsen, particularly while treatment is being reduced or after an infection. Also contact them about fevers or frequent infections during immune-suppressing treatment.

Questions to Ask Your Doctor

  1. 1.What testing will we use to look for a tumor, and will scans need to be repeated if nothing is found?
  2. 2.Are you recommending starting several treatments at once or adding them step by step, and why?
  3. 3.How will we measure whether treatment is working, and how slowly will it be reduced?
  4. 4.What signs of relapse should we watch for, and what should we do if we see them?
  5. 5.What therapies, developmental assessments or school support should we plan for, and when can routine vaccines resume?

Last reviewed • Oct 2026

Educational content, not medical advice.